Merck & Co. (MRK) › Analysis

Merck & Co. (MRK) stock analysis, November 3, 2026: Uptrend intact, but pullback leaves no clear edge

Published November 3, 2026 · MRK chart, levels and live analysis

Merck & Co. (MRK) fell 3.15% on November 3, 2026 to $143.69, five days after third-quarter results showed sales up 5% to $18.1 billion. The stock is still above its 40-week average, so the long-term uptrend is intact. It has slipped below its 50-day average and trails its sector. For the next two to six weeks the balance of evidence is even, with low conviction.

Why it matters

The event was the third-quarter report on October 29. According to the SEC filing, worldwide sales were $18.1 billion, up 5% (4% excluding currency). Keytruda and Keytruda Qlex brought in $8.6 billion, up 6%, and Winrevair reached $694 million, up 93%. Non-GAAP earnings were $2.49 a share against $2.04 on a GAAP basis, both including a one-time item. It was a solid quarter: the franchise that carries the company is still growing, and the newer drug is scaling quickly.

The market did not treat it as a catalyst. The stock peaked at $149.88 on October 21, eight days before the report, and sits 4.1% below that close. Over the past month it is flat (+0.04%), while XLV, the healthcare sector fund, gained 10.9%. Good numbers were evidently already in the price, and money went into the sector rather than into MRK.

The five-day numbers show how the move splits. MRK is up 1.8%, the S&P 500 is down 2.1% and XLV is up 2.8%. MRK therefore held up far better than the market but trailed its sector by about 1.1 points. Today's 3.15% drop is a different matter. The S&P 500 rose 0.23% and XLV slipped 0.17%, so neither explains it. No company news in the feed explains it either; the only other filing is a board appointment effective November 1, which is routine. Volume is running about half its 20-day average, which suggests a lack of buyers more than urgent selling.

No published debate pieces on MRK are in the feed, so the argument shows up in the numbers. The case for the stock is a growing Keytruda line, a fast-growing Winrevair and a gain of 28.7% over six months. The case against is that the stock has lagged XLV by 8.3% over 50 days and cannot hold its gains even after a good report. Valuation sits between the two. Twenty-six analysts rate it a buy with a mean price target of about $160, which is 10.4% above the current price. Targets range from $105 to $186, so the spread is wide and the average says little about conviction.

What the evidence says

The long-term thesis is intact. The stock is up 37.1% year to date, trades 9.5% ahead of the S&P 500 over 200 days and sits well above its 200-day average at $127.07. It is in a pullback within a weekly uptrend, 8.2% under its 52-week high of $156.45. The pullback is not stretched: the 14-day RSI is 45, neither oversold nor strong.

For the next two to six weeks the evidence is even, and conviction is low, with none of four points scoring. The stock is below its 10-week average but above its 40-week one, so the short-term and long-term trends point in different directions. It trails the S&P 500 by 0.3% over 50 days and XLV by 8.3%, both against the trend. The pullback itself is orderly, which is why the reading is neutral rather than negative.

The strongest case against that reading is a positive one: six-month and year-to-date gains are large, the weekly trend is up, and the price sits 10.4% below the consensus target. That is a real argument for buyers returning. It does not tip the balance because the stock is under its 50-day average, is losing ground to its sector, and fell on a day when both the market and the sector were steady. It is also why conviction is not higher. The pullback has not yet found a floor, and the evidence for a turn is not there.

Levels that matter

The structure holds above $131.01, a swing zone, and the first crack comes below it. The trend ends below $127.07, the 200-day average, on a weekly close. Beneath that, $125 and $123.93 are the next supports. Those levels matter because they are where buyers have stepped in before and where the long-term average sits.

The breakout level is a daily close above $146.64, the 50-day average, on volume above its 20-day average. That would be the first sign that buyers are back. From there the targets are $153.46 (a swing zone) and $156.45 (the 52-week high). The stop sits at $129.75, a quarter of an ATR under $131.01. Against that stop the math gives only 0.4 to 1 to the first target and 0.6 to 1 to the second. That is far short of the 3 to 1 that makes a breakout worth the risk. It would take a much higher target or a much closer stop to change that, and neither is on the map today.

What would change the picture

A weekly close below $127.07, the 200-day average, would end the uptrend case and turn a pullback into a broken trend. The non-price fact that could bring that about is evidence that Keytruda growth, 6% last quarter, is fading, because that line carries the company's earnings.

What to watch

Get a message when the MRK picture changes — the agent team watches the levels and the news for you.Create a free account

More MRK analyses

Research & education, not advice. MarketCrew is AI-powered and can make mistakes.